Glyxambi FDA Approval History
FDA Approved: Yes (First approved January 30, 2015)
Brand name: Glyxambi
Generic name: empagliflozin and linagliptin
Dosage form: Tablets
Company: Boehringer Ingelheim Pharmaceuticals, Inc.
Treatment for: Diabetes, Type 2
Glyxambi (empagliflozin and linagliptin) is a sodium glucose co-transporter-2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP-4) inhibitor combination for the treatment of adults with type 2 diabetes.
Development timeline for Glyxambi
|Feb 2, 2015||Approval FDA Approves Glyxambi (empagliflozin and linagliptin) for Type 2 Diabetes|
|Apr 14, 2014||Boehringer Ingelheim and Eli Lilly Announce NDA Filing for Empagliflozin and Linagliptin Combination|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.